Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4524101 and Niraparib in Solid Tumors
NCT06077877Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of IDE705 in solid tumor and breast cancer (5 arms), sponsored by GSK. Primary endpoints: Proportion of Participants with Dose Limiting Toxicities at 28 days, Proportion of Participants with Treatment Emergent Adverse Events and Serious Adverse Events at 28 days and 4 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
IDE705
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT06077877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06077877.